Clinical trials: in Belarus
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL).
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PACIFICA (NCT03165734)
- Testing
- Pacritinib, Physician's Choice medications
- Where
- 207 sites in United States, Australia and 22 more
- Volunteers
- 407 people
- Sponsor
- Swedish Orphan Biovitrum
Sialorrhea
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
- Trial name
- OPTIMYST (NCT02610868)
- Testing
- MYOBLOC
- Where
- 35 sites in United States, Belarus and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Large B-Cell Lymphoma (LBCL)
Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory large B-cell lymphomas (R/R LBCLs) since 2018.
- Trial name
- NCT07524816
- Testing
- CAR-T cell therapy
- Where
- Belarus
- Volunteers
- 76 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were…
- Trial name
- NCT02859727
- Testing
- CDZ173
- Where
- 8 sites in United States, Belarus and 5 more
- Volunteers
- 37 people
- Sponsor
- Pharming Technologies B.V.
Ovarian Cancer, Fallopian Tube Cancers
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07472140
- Testing
- PARP inhibitor + Bevacizumab, PARP inhibitor
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Gastric Cancer, Esophageal Cancer
Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
GASTROBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of gastric and esophageal cancer
- Conditions
- Gastric Cancer, Esophageal Cancer, Brain Metastases
- Trial name
- GASTROBRAIN (NCT07448493)
- Testing
- Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR), Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT), Combined Local Treatment Modalities
- Where
- 15 sites in Belarus, Russia
- Volunteers
- 230 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Colorectal Cancer, Brain Metastases, Adult
Local Treatment Strategies for Brain Metastases of Colorectal Cancer
COLBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of colorectal cancer.
- Trial name
- COLBRAIN (NCT07448662)
- Testing
- Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR), Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT), Combined Local Treatment Modalities
- Where
- 15 sites in Belarus, Russia
- Volunteers
- 700 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior…
- Trial name
- ROSEWOOD (NCT03332017)
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 217 people
- Sponsor
- BeiGene
Ulcerative Colitis (UC)
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had…
- Trial name
- U-ACTIVATE (NCT03006068)
- Testing
- Upadacitinib (ABT-494)
- Where
- 492 sites in United States, Argentina and 44 more
- Volunteers
- 950 people
- Sponsor
- AbbVie
Chronic Kidney Disease
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney…
- Trial name
- NCT00858637
- Testing
- MCI-196, Simvastatin
- Where
- 39 sites in Belarus, Bulgaria and 11 more
- Volunteers
- 260 people
- Sponsor
- Tanabe Pharma Corporation
Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to…
- Trial name
- PERSEUS (NCT04458051)
- Testing
- Tolebrutinib
- Where
- 277 sites in United States, Argentina and 40 more
- Volunteers
- 767 people
- Sponsor
- Sanofi
Ulcerative Colitis
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT02531126
- Testing
- RPC1063
- Where
- 41 sites in United States, Australia and 18 more
- Volunteers
- 877 people
- Sponsor
- Celgene
Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression…
- Trial name
- FIRST (NCT03602859)
- Testing
- Niraparib, Dostarlimab (TSR-042), Standard of care
- Where
- 182 sites in United States, Belarus and 17 more
- Volunteers
- 1,400 people
- Sponsor
- Tesaro, Inc.
Sepsis
Algorithm for Predicting the Unfavorable Course of Sepsis in Children
A comprehensive strategy will be used to investigate the relationship and correlation between 4 diagnostically significant markers relevant for early diagnosis and prediction of complications and death in the development of…
- Trial name
- NCT05908162
- Testing
- Bood leukocyte subsets
- Where
- Belarus
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- The Republican Research and Practical Center for Epidemiology and Microbiology
Prostate Cancer Patients Undergoing Radical Prostatectomy
Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advanced Prostate Cancer
This is a randomized controlled study assessing outcome of low (no or limited) versus high (limited or extended) extent of lymph node dissection in addition to radical prostatectomy in patients with operable localized or locally…
- Trial name
- NCT07308990
- Testing
- Radical prostatectomy with extended / limited lymph node dissection, Radical prostatectomy with limited / no lymph node dissection
- Where
- Belarus
- Volunteers
- 800 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Diabetes Mellitus
The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells
The purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.
- Trial name
- NCT05207995
- Testing
- Autologous tolerogenic dendritic cells, Standard treatment according to the clinical protocols
- Where
- Belarus
- Volunteers
- 32 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Carotid Artery Diseases, Carotid Atherosclerosis
Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
Cerebral hyperperfusion syndrome (CHS) was initially described as a clinical complication following carotid endarterectomy (CEA), but it may occur after both CEA and carotid artery stenting.
- Conditions
- Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Artery Stenosis, Cerebral Hyperperfusion Syndrome
- Trial name
- NCT05800821
- Testing
- Carotid revascularization
- Where
- Belarus
- Volunteers
- 500 people
- Sponsor
- State Institution "Republican Scientific and Practical Center" Cardiology, Belarus
Acute Cerebrovascular Accident, Myocardial Infarction (MI)
Clinical Profile of a Patient After MI and ACVA Based on Outpatient Register Data
This is a retrospective observational study using the methodology of creating medical registries. The expected number of patients included in the registry is about 2000 patients with myocardial infarction and/or ACVD of any…
- Trial name
- NCT07159698
- Where
- Belarus
- Volunteers
- 1,520 people
- Sponsor
- State Institution "Republican Scientific and Practical Center" Cardiology, Belarus
Crohn Disease
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03440372
- Testing
- Ozanimod
- Where
- 408 sites in United States, Argentina and 33 more
- Volunteers
- 625 people
- Sponsor
- Celgene